LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen

医学 阿替唑单抗 内科学 养生 吉西他滨 紫杉烷 肿瘤科 临床终点 长春瑞滨 化疗方案 临床研究阶段 化疗 癌症 临床试验 顺铂 乳腺癌 免疫疗法 彭布罗利珠单抗
作者
Siow Ming Lee,Christian Klaus Jochen Schulz,K. Prabhash,B. Han,Aleksandra Szczęsna,D.L. Cortinovis,A. Rittmeyer,David Vicente Baz,Raffaele Califano,Le Tuan Anh,G. Liu,F. Cappuzzo,Jessica Reyes Contreras,Martin Reck,Youyou Hu,S. Morris,E.K. Hoeglander,M. Connors,Hans Kristian Moen Vollan,Solange Peters
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:33: S1418-S1419 被引量:21
标识
DOI:10.1016/j.annonc.2022.08.052
摘要

In IMpower110 (NCT02409342), 1L atezo (anti–PD-L1) improved OS vs platinum-doublet chemo (PDC) in pts with PD-L1–high NSCLC and ECOG PS ≤1. However, ≥40% of NSCLC pts have poor ECOG PS (≥2) and/or substantial comorbidities, resulting in ineligibility for platinum-based chemo and most 1L clinical trials. IPSOS is a global, multicenter, open-label, randomised Phase 3 study of atezo vs single-agent chemo in pts ineligible for 1L PDC. Pts had locally advanced/metastatic NSCLC without driver mutations and were ineligible for 1L PDC due to poor PS (≥2) or comorbidities in pts aged ≥70 yr. Pts were randomised 2:1 to atezo 1200 mg IV every 3 wk or single-agent chemo (vinorelbine or gemcitabine) in 3- or 4-wk cycles. The primary endpoint was OS. Key secondary endpoints were OS rates, ORR, PFS, DOR and OS and PFS in PD-L1+ pts. Safety and health-related quality of life were also assessed. 453 pts were randomised (302 atezo; 151 chemo). Median age was 75 yr (range, 33-94), 31% were ≥80 yr, 72% were male and 83% had ECOG PS ≥2. At data cutoff (30 Apr 2022), with a median follow-up of 41.0 mo, atezo significantly improved OS vs chemo (stratified HR, 0.78; 95% CI: 0.63, 0.97; P=0.028), with a consistent benefit seen across key subgroups, including PD-L1 expression levels, PS and histology. Benefit was seen in 2-yr OS rate, ORR and DOR (Table). Gr 3/4 TRAEs occurred in 16.3% and 33.3% of pts and Gr 5 TRAEs in 1.0% and 2.7% of pts in the atezo and chemo arms, respectively. Atezo improved TTCD of chest pain vs chemo (HR, 0.51; 95% CI: 0.27, 0.97); meaningful improvements from baseline were also seen for appetite loss and cough. 1L atezo improved OS vs chemo in platinum-ineligible pts with NSCLC, with twice as many pts estimated to be alive at 2 yr when treated with atezo vs chemo. No new or unexpected safety concerns were seen in this poor prognosis population.Table: LBA11Atezo (n=302)Chemo (n=151)HRa95% CImOS (95% CI), mo10.3 (9.4, 11.9)9.2 (5.9, 11.2)0.78 (0.63, 0.97)P=0.0281-yr OS (95% CI), %43.7 (37.9, 49.4)38.6 (30.5, 46.7)–2-yr OS (95% CI), %24.3 (19.3, 29.4)12.4 (6.7, 18.0)–mPFS (95% CI), mo4.2 (3.7, 5.5)4.0 (2.9, 5.4)0.87 (0.70, 1.07)ORR (95% CI), %16.9 (12.8, 21.6)7.9 (4.2, 13.5)–mDOR (95% CI), mo14.0 (8.1, 20.3)7.8 (4.8, 9.7)–aStratified. Open table in a new tab

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
瓶瓶大王完成签到 ,获得积分10
刚刚
傅凡桃完成签到,获得积分10
刚刚
大模型的应助被拉长的砖家采纳,获得10
刚刚
里里完成签到,获得积分10
刚刚
kyhappy_2002完成签到,获得积分10
刚刚
光亮的洙完成签到,获得积分10
1秒前
1秒前
天天向上的应助被路遥知马力采纳,获得10
2秒前
2秒前
榴莲味月饼完成签到 ,获得积分10
2秒前
工作热情仔的应助被xyz采纳,获得100
2秒前
lijiaqi完成签到 ,获得积分10
2秒前
zhi完成签到,获得积分10
3秒前
yu发布了新的文献求助20
3秒前
3秒前
戒骄戒躁完成签到 ,获得积分10
3秒前
认真的小刺猬完成签到,获得积分10
4秒前
4秒前
彭彭完成签到,获得积分10
4秒前
慕青的应助被研友_ZG4ml8采纳,获得10
5秒前
图南完成签到,获得积分10
5秒前
Alex111完成签到,获得积分10
5秒前
橘子完成签到,获得积分20
6秒前
自由灵安完成签到,获得积分10
6秒前
fhn716完成签到,获得积分10
6秒前
6秒前
爱笑的枫叶完成签到,获得积分10
6秒前
6秒前
山楂完成签到,获得积分10
7秒前
科研民工完成签到,获得积分10
7秒前
NexusExplorer的应助被111采纳,获得10
7秒前
合适抽屉完成签到 ,获得积分10
7秒前
名取周一发布了新的文献求助10
8秒前
Owen的应助被小黑球采纳,获得10
9秒前
yunt完成签到 ,获得积分0
9秒前
五六87完成签到,获得积分10
9秒前
hele完成签到,获得积分10
9秒前
TJway发布了新的文献求助10
9秒前
橘子发布了新的文献求助10
9秒前
yjzzz完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039